Fondaparinux
- Generic Name
- Fondaparinux
- Brand Names
- Arixtra
- Drug Type
- Small Molecule
- Chemical Formula
- C31H53N3O49S8
- CAS Number
- 104993-28-4
- Unique Ingredient Identifier
- J177FOW5JL
- Background
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high...
- Indication
Approved for: (1) prophylaxis of VTE for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement and knee surgery; (2) prophylaxis of VTE patients undergoing abdominal surgery who are at high risk of thromboembolic complications (e.g. patients undergoing abdominal cancer surgery); (3) tr...
- Associated Conditions
- Acute Pulmonary Embolism (PE), Deep Vein Thrombosis, Non ST Segment Elevation Myocardial Infarction (NSTEMI), ST Segment Elevation Myocardial Infarction (STEMI), Unstable Angina Pectoris, Acute, superficial, symptomatic Vein Thrombosis
- Associated Therapies
- -
Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2012-04-24
- Lead Sponsor
- Università degli Studi dell'Insubria
- Target Recruit Count
- 206
- Registration Number
- NCT00927602
- Locations
- 🇮🇹
University Of Insubria, Varese, Italy
Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm
- Conditions
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2012-10-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 349
- Registration Number
- NCT00911300
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
- Conditions
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 39
- Registration Number
- NCT00911157
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients
- Conditions
- Interventions
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 198
- Registration Number
- NCT00894283
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures
- Conditions
- Interventions
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Red Cross Hospital Beverwijk
- Target Recruit Count
- 669
- Registration Number
- NCT00881088
- Locations
- 🇳🇱
Medical Center Alkmaar, Alkmaar, North Holland, Netherlands
🇳🇱University Medical Center Nijmegen, Nijmegen, Gelderland, Netherlands
🇳🇱Red Cross Hospital, Beverwijk, N-Holland, Netherlands
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1351
- Registration Number
- NCT00843492
- Locations
- 🇪🇸
GSK Investigational Site, Vigo/Pontevedra, Spain
A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Prairie Education and Research Cooperative
- Target Recruit Count
- 78
- Registration Number
- NCT00789399
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 3
- Registration Number
- NCT00673439
- Locations
- 🇺🇸
University of Louisville Hospital, Louisville, Kentucky, United States
Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression
- Conditions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00659399
- Locations
- 🇺🇸
NYU Cancer Institute Clinical Cancer Center, New York, New York, United States
Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Methodist Healthcare
- Registration Number
- NCT00603824
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.